Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Yuhan CDMO | Contract Pharma

What are you searching for?

Sign in

Search by

Yuhan CDMO

Yuhan CDMO

Company Headquarters

74, Noryanjin-ro, Dongjak-gu, Seoul, KR

Driving Directions Phone: View Phone Fax: View Fax
View website

Company Description

Yuhan, founded in 1926 in South Korea, provides one-stop CDMO services for small molecule drug substances with its scale-up expertise. As a full-spectrum CDMO service provider, Yuhan CDMO offers customized services for small molecule intermediates and APIs with best quality and reliability.

Request more information from Yuhan CDMO

Request more information from Yuhan CDMO

Categories from Yuhan CDMO

Chemical Analysis
CMC (Chemistry, Manfacturing & Controls)
Contract Development and Manufacturing Organization (CDMO)
Contract Manufacturing
Custom Manufacturing
Manufacturing, API
Manufacturing, Custom
Methods Development
Methods Validation
Micronization
Process Analytical Technology (PAT)
Process Development/Scale-Up Services
Process R&D
Process Validation Studies
Project Management
QA/QC
R&D Services
Stability, ICH
Validation, Manufacturing

Content From Yuhan CDMO

Continuous Flow Chemistry: Revolutionizing Pharma Manufacturing

Sponsored Content

Continuous Flow Chemistry: Revolutionizing Pharma Manufacturing

From complex challenges to innovative solutions, explore how continuous flow technology is transforming drug substance production efficiency and safety.

Released By Yuhan CDMO

Related Content

Collaborations & Alliances

Boehringer, Yuhan Enter NASH Pact

To develop dual agonist for the treatment of NASH and related liver diseases that combines GLP-1 and FGF21 activity in one molecule

Collaborations & Alliances

Gilead, Yuhan Enter Licensing Agreement

To co-develop novel therapeutic candidates for the treatment of patients with advanced fibrosis due to nonalcoholic steatohepatitis

Breaking News

Yuhan and Shandong Luoxin Form Pact

Enter license and co-development agreement for third generation EGFR-targeted therapy in China

Breaking News

Yuhan And Sorrento Therapeutics Form JV

ImmuneOnica Therapeutics strengthens both companies in immuno-oncology